Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 37: 169-172, 1991;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kunishima, S.
Right arrow Articles by Ohno, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kunishima, S.
Right arrow Articles by Ohno, R.

Clinical Chemistry, Vol 37, 169-172, Copyright © 1991 by American Association for Clinical Chemistry

New enzyme-linked immunosorbent assay for glycocalicin in plasma

S Kunishima, K Hayashi, S Kobayashi, T Naoe and R Ohno
Department of Central Clinical Laboratory, Meijo Hospital, Nagoya, Japan.

A new sandwich-type enzyme-linked immunosorbent assay for quantifying glycocalicin, a proteolytic fragment of platelet membrane glycoprotein Ib, is described. The assay is based on the use of two monoclonal antibodies raised against glycoprotein Ib and involves the avidin- biotin technique. The detection limit is 7 micrograms/L and the range of glycocalicin determined in plasma is 0.01 to 1 mg/L. Assay time is 2 h. The intra-assay CV ranged from 3.6% to 5.2%, the interassay CV from 5.4% to 8.0%. Analytical recovery of purified glycocalicin added to a plasma pool averaged 96%. In 36 healthy subjects, the mean glycocalicin concentration in plasma was 0.36 (SD 0.07) mg/L (2.7 nmol/L). We conclude that this assay is suitable for measuring glycocalicin in plasma and is also more sensitive and precise than the previously published immunoassays based on competitive binding assay.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Pathol.Home page
K. Takeshita, M. Hayashi, S. Iino, T. Kondo, Y. Inden, M. Iwase, T. Kojima, M. Hirai, M. Ito, D. J. Loskutoff, et al.
Increased Expression of Plasminogen Activator Inhibitor-1 in Cardiomyocytes Contributes to Cardiac Fibrosis after Myocardial Infarction
Am. J. Pathol., February 1, 2004; 164(2): 449 - 456.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Kunishima, J. A. Lopez, S. Kobayashi, N. Imai, T. Kamiya, H. Saito, and T. Naoe
Missense Mutations of the Glycoprotein (GP) Ibbeta Gene Impairing the GPIb alpha /beta Disulfide Linkage in a Family With Giant Platelet Disorder
Blood, April 1, 1997; 89(7): 2404 - 2412.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Association for Clinical Chemistry.